Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Advances in delivering small interfering RNAs to specific tissues may bring these nucleotides closer to reality as therapeutic agents.
The author is in the Department of Biopharmaceutical Sciences and Pharmaceutical Chemistry, University of California, San Francisco, CA 94143-0446, USA. E-mail: szoka{at}cgl.ucsf.edu
The editors suggest the following Related Resources on Science sites:
In Science Magazine
REPORTS
Dan Peer, Eun Jeong Park, Yoshiyuki Morishita, Christopher V. Carman, and Motomu Shimaoka (1 February 2008) Science319 (5863), 627.
[DOI: 10.1126/science.1149859] |Abstract »|Full Text »|PDF »|Supporting Online Material »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides.
X. Ming, K. Carver, M. Fisher, R. Noel, J.-C. Cintrat, D. Gillet, J. Barbier, C. Cao, J. Bauman, and R. L. Juliano (2013)
Nucleic Acids Res.
41, 3673-3687
|Abstract »|Full Text »|PDF »
Targeting Melanoma Growth and Metastasis with Systemic Delivery of Liposome-Incorporated Protease-Activated Receptor-1 Small Interfering RNA.
G. J. Villares, M. Zigler, H. Wang, V. O. Melnikova, H. Wu, R. Friedman, M. C. Leslie, P. E. Vivas-Mejia, G. Lopez-Berestein, A. K. Sood, et al. (2008)
Cancer Res.
68, 9078-9086
|Abstract »|Full Text »|PDF »
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.
R. Juliano, Md. R. Alam, V. Dixit, and H. Kang (2008)
Nucleic Acids Res.
36, 4158-4171
|Abstract »|Full Text »|PDF »
